The CLL Society provides information on these surveys as a service to our readers. It does not endorse or recommend any marketing surveys and urges all to decide according to their own preferences.
CLL/SLL Patient Survey for Lymphoma Canada
If you have been treated with venetoclax + obinutuzumab (Gazya) or with acalabrutinib (Calquence), you can help a fellow CLL patients in Canada gain access to these therapies by completing a brief survey. You do not have to live in Canada to help.
Rare Disease (RD) researchers at Oregon State University are planning a project that examines how individuals with blood cancers manage their cancer-related fatigue. This group has a strong record of communicating their findings to rare disease patients, the scientific community, and policymakers, including publishing in top psychology journals and presenting at international scientific and rare disease conferences.